A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis

Nature Clinical Practice Rheumatology

Volumn 5, Issue 3, 2009, Pages 132-133

  Williams, Frances M K ^a   Spector, Tim D ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 O ACETYL 11 KETA BETA BOSWELLIC ACID; 5 LOXIN; ANALGESIC AGENT; BOSWELLIA SERRATA EXTRACT; BOSWELLIC ACID; LICOFELONE; LIPOXYGENASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG; ZILEUTON;

ALTITUDE DISEASE; ASTHMA; BOSWELLIA; BOSWELLIA SERRATA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; NOTE; OSTEOARTHRITIS; PRIORITY JOURNAL;

EID: 62849122750     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum1006     Document Type: Note

References (5)

1. Luo W et al. (2007) The burden of adult obesity in Canada. Chronic Dis Can 27: 135-144
2. Lopez AD et al. (2006) Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 367: 1747-1757
3. Sengupta K et al. (2008) A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther 10: R85
4. Watkins PB et al. (2007) Clinical pattern of zileuton-associated liver injury: Results of a 12-month study in patients with chronic asthma. Drug Saf 30: 805-815
5. Raynauld JP et al. (2008) Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multi-centre clinical trial using quantitative MRI. Ann Rheum Dis [doi:10.1136/ ard.2008.088732]